Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Adjuvance

Adjuvance
2009 FOUNDED
PRIVATE STATUS
Series A1 LATEST DEAL TYPE
$20M LATEST DEAL AMOUNT
4 INVESTORS
Description

Operator of a bio-pharmaceutical company designed to offer vaccines. The company's SAPONEX products are critical components that are added to many vaccines, enabling people to improve their immunity system.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Pharmaceuticals
Primary Office
  • 1225 L Street
  • Suite 600
  • Lincoln, NE 68508
  • United States

+1 (402) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Adjuvance’s full profile, request a free trial.

Adjuvance Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series A1) 29-Jan-2020 $20M 000.00 0000 Completed Pre-Clinical Trials
2. Seed Round 29-Aug-2019 00.00 00.00 Completed Pre-Clinical Trials
1. Grant 31-May-2015 $1.5M Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Adjuvance Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A-1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A-2 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

Adjuvance Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Morningside Venture Capital Venture Capital Minority 000 0000 000000 0
Invest Nebraska Venture Capital Minority 000 0000 000000 0
Mont Alto Capital Family Office Minority 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0

Adjuvance Executive Team (9)

Name Title Board
Seat
Contact
Info
Tyler Martin Chairman & Chief Executive Officer
Stephan Schulze Chief Financial Officer
Patrick Giljum Chief Technology Officer
Jeffrey Gardner Co-Founder, Board Member & Chief Business Officer
Sean Bennett CMO

2 Former Executives

You’re viewing 5 of 9 executives. Get the full list »

Adjuvance Board Members (9)

Name Representing Role Since Contact
Info
Gregory Poland Adjuvance Vice Chairman & Advisor 000 0000
Isaac Cheng MD Self Board Member 000 0000
John Gallo Adjuvance Board Member 000 0000
Ken Kelley Adjuvance Board Member 000 0000
Mary Gin Adjuvance Board Member 000 0000

2 Former Board Members

You’re viewing 5 of 9 board members. Get the full list »